Michael L. Cheng

MD

Thoracic medical oncologist

Dr. Michael L. Cheng is a medical oncologist who cares for patients with lung cancer and other tumors affecting the chest, with a particular focus on non-small cell lung cancer. He strives to provide individualized, compassionate care through precision oncology (using the genetic profile of the patient's cancer to custom-tailor treatment).

Cheng leads research centered on advancing cancer genomics and developing improved treatments for patients, including through clinical trials to evaluate new targeted therapies and immunotherapies for lung cancer. He is inspired by how research discoveries can lead to tangible benefits for patients.

Cheng earned his medical degree from the David Geffen School of Medicine at UCLA. He completed a residency in internal medicine at UCSF and a fellowship in medical oncology at Memorial Sloan Kettering Cancer Center. Before joining the UCSF faculty, he served as an assistant professor at the Dana-Farber Cancer Institute and Harvard Medical School.

Cheng is a member of the American Society of Clinical Oncology (ASCO), American Association for Cancer Research and International Association for the Study of Lung Cancer. He has received the Career Development Award from Conquer Cancer, the ASCO Foundation.

  • Education

    UCLA, MD, 2012

  • Residencies

    UCSF, Internal Medicine, 2015

  • Fellowships

    Memorial Sloan Kettering, Medical Oncology, 2018

  • Academic Title

    Associate Professor

Conditions I specialize in

Where I see patients (1)

    Selected research

    See all research
    Decorative Caduceus

    Study of RAS(ON) Inhibitor Combinations in Patients with Advanced RAS-mutated NSCLC

    Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs and clinically significant changes in laboratory values, ECGs and vital signs

    Recruiting

    Decorative Caduceus

    A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer...

    The time from date of randomization to date of death due to any cause.

    Recruiting

    Decorative Caduceus

    Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

    Evaluation of DLT of CHS-388 as a monotherapy.

    Recruiting

    Decorative Caduceus

    Study of ORIC-114 in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

    RP2D as determined by interval 3+3 dose escalation design

    Recruiting

    Contact me

    Share